ESC Congress 2026 Abstract
An oral drug lowers lipoprotein(a) across patient groups
In two pooled randomized trials, daily enlicitide lowered lipoprotein(a) across all starting levels, with the largest absolute reduction of 46.8 nanomoles per liter…In two pooled randomized trials, daily enlicitide lowered lipoprotein(a) across all starting levels, with the largest absolute reduction of 46.8 nanomoles per liter versus placebo.
Randomized trial · 3,212 peopleInterventions
Who was studied3,212 adults with or without prior major cardiovascular events, against placebo
What changedLipoprotein(a) fell across all starting levels, with a reduction of 46.8 nanomoles per liter versus placebo in the highest quarter
The catchCardiovascular events and side effects were not reported